Bristol Myers Squibb Company BMY
62.86
1.36
2.21%
as of 25 Sep
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bristol Myers Squibb Company (BMY) Debt to equity
Bristol Myers Squibb Company's debt to equity at the end of the quarter to 30 June 2026 was 1.9×, down 0.5× from fiscal 2025 (2.4×). Over the past ten years it has ranged from 0.4× (fiscal 2016) to 3.0× (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 2.4× | (19.54%) |
| FY2024 | 3.0× | 124.60% |
| FY2023 | 1.3× | 6.75% |
| FY2022 | 1.3× | 2.12% |
| FY2021 | 1.2× | (7.50%) |
| FY2020 | 1.3× | 47.98% |
| FY2019 | 0.9× | 73.78% |
| FY2018 | 0.5× | (22.60%) |
| FY2017 | 0.7× | 63.77% |
| FY2016 | 0.4× | (11.49%) |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 1.9× | (12.65%) |
| Mar 2026 | 2.2× | (9.27%) |
| Dec 2025 | 2.4× | (7.43%) |
| Sep 2025 | 2.6× | (6.37%) |
| 42 more quarters | Free account |
Against its own ten years
Low 0.4×
High 3.0×
Ten-year median
1.2×
Current reading's percentile
91
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| SNY Sanofi compare | 0.3× |
| AZN AstraZeneca PLC compare | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| GSK GSK PLC Sponsored ADR compare | 1.1× |
| NVS Novartis AG compare | 1.1× |
| BMY Bristol Myers Squibb Company | 1.9× |
| GILD Gilead Sciences, Inc. compare | 2.2× |
| AMGN Amgen Inc. compare | 4.9× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement